Global Health Limited reported robust growth for the fiscal year ended March 31, 2026. The company achieved a consolidated annual revenue of ₹44,102.66 million, marking a significant increase from the previous year. Alongside these strong results, the Board of Directors has recommended a final dividend of ₹0.50 per equity share, reflecting continued value creation for shareholders. The company also announced strategic leadership changes to support its ongoing growth and expansion initiatives.
Financial Performance Highlights
For the financial year ended March 31, 2026, Global Health Limited showcased impressive financial health. The company’s consolidated revenue from operations rose to ₹44,102.66 million, up from ₹36,923.45 million in the previous fiscal year. Consolidated profit after tax reached ₹5,540.68 million, a notable increase from ₹4,813.18 million in the prior year. On a standalone basis, the company reported a profit after tax of ₹4,962.01 million.
Dividend and Shareholder Value
Reflecting the company’s strong performance, the Board of Directors has recommended a final dividend of ₹0.50 per equity share, representing a 25% payout on the face value of ₹2 per share. This dividend is subject to approval by the shareholders at the upcoming Annual General Meeting (AGM) and will be disbursed within 30 days following the meeting.
Strategic Expansions and Leadership Changes
The company continues to pursue aggressive expansion. During the fourth quarter, it finalized a built-to-suit lease arrangement for a 400-bed multi-specialty hospital in Varanasi. Furthermore, it has entered into a Business Transfer Agreement to acquire a 79-bedded Advanced Super Speciality Hospital in Indore.
The Board also announced leadership updates effective May 14, 2026: Mr. Kedar Ashok Apte has been appointed as the Chief Marketing & Growth Officer, and Mr. Jagdeep Singh has been appointed as the General Counsel. Concurrently, the company noted the upcoming resignation of Ms. Richa Singh, effective May 20, 2026.
Source: BSE
